

# CoNCERT Pharmaceuticals, Inc.

## Corporate Headquarters:

65 Hayden Avenue  
Suite 3000N  
Lexington, MA 02421  
Tel: 781.860.0045

**Founded:** April 2006

**Nasdaq Listed:** CNCE

## Co-Founders:

Richard Aldrich  
Roger Tung  
Christoph Westphal

**Employees:** Approximately 70

## Third Quarter 2021 Financial Results

Cash: \$103.7M  
Raised an additional \$65M in November 2021\*

\*Announced an agreement with BVF Partners L.P. and RA Capital Management to raise gross proceeds of \$65 million on November 4, 2021.

## Investor and Media Contact:

Justine E. Koenigsberg  
Senior Vice President, Corporate Communications and Investor Relations  
Tel: 781.674.5284  
Email: IR@concertpharma.com

[www.concertpharma.com](http://www.concertpharma.com)

@ConcertPharma



Concert Pharmaceuticals is a clinical stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert applies its proprietary DCE Platform<sup>®</sup> (deuterated chemical entity) to approved drugs that we believe can be improved with deuterium substitution to provide better pharmacokinetic or metabolic properties and thereby enhance clinical safety, tolerability or efficacy. Because Concert's new chemical entities are deuterated versions of existing and validated drugs, they are expected to have a high probability of clinical success and achieve early clinical proof-of-concept. By leveraging the large body of knowledge on known drugs, Concert focuses its efforts on valuable opportunities where deuterium modification may provide an important medical benefit.

Potential advantages of our selective deuteration include:

- *Improved metabolic profile.* We have selectively deuterated compounds and compounds produced by metabolism of other compounds, which are called metabolites, to improve their metabolic profiles by reducing the formation of toxic or reactive metabolites or by increasing the formation of desired, active metabolites relative to the corresponding non-deuterated compound. The improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions.
- *Improved oral bioavailability.* We have selectively deuterated compounds to reduce the extent of undesired metabolism in the wall of the intestines and in the liver, referred to as first-pass metabolism. This resulted in a larger percentage of unmetabolized drug reaching the target site of action. Deuterated compounds with improved bioavailability may be active at lower doses.
- *Increased half-life.* We have selectively deuterated compounds to prolong their pharmacokinetic profile, which is an increase in the half-life of the compound in the body. This may decrease the number of doses that a patient is required to take per day or provide more consistent exposure of the compound in comparison to the corresponding non-deuterated compound.

Selective replacement of specific hydrogen atoms with deuterium creates new compounds that retain the pharmacological effectiveness of the validated drug molecules but, in select cases, improve metabolic profiles. Deuterium is a safe, non-radioactive relative of hydrogen that can be isolated from sea water and has been used extensively in human metabolic and clinical studies. The average adult human body contains 1-2<sup>+</sup> grams of deuterium due to its general abundance in nature.

## Late-Stage Clinical Asset Advancing In Phase 3 Evaluation

	Product Candidate	Lead Indications	Phase 1	Phase 2	Phase 3	Market	Worldwide Rights
Autoimmune Diseases	<b>CTP-543</b> Deuruxolitinib	Alopecia Areata: Phase 3 THRIVE-AA1 Ongoing					
	Alopecia Areata: Phase 3 THRIVE-AA2 Ongoing						
	Alopecia Areata: Open Label, Long-Term Extension Ongoing						
	Alopecia Areata: Additional NDA-Supporting Studies						

## Management Team:

Roger Tung, Ph.D.  
Co-Founder, President and CEO

Marc Becker  
Chief Financial Officer

James Cassella, Ph.D.  
Chief Development Officer

Jeffrey Munsie  
Chief Legal Officer

Nancy Stuart  
Chief Operating Officer

Justine Koenigsberg  
Senior Vice President, Corporate  
Communications and Investor Relations

Christopher Brummel, Ph.D.  
Vice President, DMPK and Bioanalysis

Christine Boisclair  
Vice President, Regulatory Affairs and  
Quality Assurance

Cameron Cowden, Ph.D.  
Vice President, Pharmaceutical  
Development

Nabil Uddin, Pharm.D.  
Vice President, Corporate Development

Darren Wong, Ph.D.  
Vice President, Pharmacology and  
Toxicology

## Board of Directors:

Richard Aldrich  
Chairman of the Board; Co-founder and  
Partner, Longwood Founders Fund

Thomas G. Auchincloss, Jr.  
Managing Partner, Counterpoint Trading  
Company

Ronald Barrett, Ph.D.  
CEO and Chairman, Medikine

Jesper Høiland  
Global Chief Commercial Officer,  
Ascendis Pharma A/S

Peter Barton Hutt  
Senior Counsel, Covington and Burling;  
Former Chief Counsel, FDA

Wilf Jaeger, M.D.  
Former Partner and Founder,  
Three Arch Partners

Roger Tung, Ph.D.  
President and CEO  
Concert Pharmaceuticals, Inc.


Christine van Heek  
Former Corporate Officer and President,  
Therapeutics Division  
Genzyme Corporation

## DCE Platform®

Selective incorporation of deuterium in place of hydrogen has the unique benefit of retaining the biochemical potency and selectivity of physiologically active compounds while, in select instances, modifying their metabolic properties to substantially alter their overall therapeutic profile. By starting from compounds with well-defined human pharmacological effects such as approved drugs, deuterium chemistry offers a unique, conceptually straightforward approach to creating significantly differentiated, patentable new medicines that can address important unmet medical needs.

## Deuterium

Deuterium is a safe, naturally-occurring relative of hydrogen. Deuterium possesses physicochemical properties that are very similar to those of hydrogen, but its atomic mass is double that of hydrogen. Because of its increased mass, deuterium forms significantly stronger bonds with carbon. Many drugs are metabolized by pathways that involve scission of carbon-hydrogen bonds. Concert exploits the strong deuterium-carbon bonds to improve metabolic profiles, improve oral bioavailability and increase half-life. While deuterium chemistry has a long history of use in the clinical setting – primarily to study bioavailability and drug metabolism. Concert is the first company solely dedicated to the use of deuterium as a drug platform with the goal of creating novel medicines that address commercially important needs.



## Broad Patent Estate and Intellectual Property

We protect our product candidates through the use of patents, trade secrets and careful monitoring of our proprietary know-how. Our patent portfolios are wholly owned by us. They include issued patents or patent applications that claim deuterated analogs of more than 90 non-deuterated drugs and drug candidates. In early 2009, the first patents were granted to Concert by the U.S. Patent and Trademark Office (USPTO) with claims to novel compositions of matter. The DCE Platform® has to date resulted in more than 100 issued US patents. In addition to its patent estate, Concert also has industry-leading expertise and know-how for developing, optimizing, analyzing, and manufacturing deuterium drug compounds.